Jeena Sikho Lifecare Limited — PPTs, 12-11-2024: Investor Presentation

**Financial Highlights:** Jeena Sikho Lifecare Limited reported significant growth in the half-year ended September 2024, achieving a revenue from operations of ₹21,413 lakh, marking a 36% year-on-year increase. Gross profit improved by 35% to ₹19,236 lakh, sustaining a robust gross margin of 89.83%. Operating expenses rose by 37%, resulting in an EBITDA of ₹5,928 lakh and an EBITDA margin of 28%. Profit after taxes climbed 47% to ₹4,688 lakh, demonstrating strong earnings momentum.

**Strategic Initiatives and Growth Drivers:** The company expanded its operational bed count to 1,530, a 20% increase from the previous year, contributing positively to IPD volumes with an average utilization rate of 51%. Plans are underway to launch additional centers and tap into OTC medicine sales to enhance revenue streams further.

**Business Developments:** With over 100 active operational centers across 21 states, JSLL is executing a pipeline of 20 new facilities, which promises to bolster its market presence and cater to a broader customer base.

**Market Position and Competitive Advantage:** As a top player in the Ayurveda healthcare sector, JSLL holds approximately 11% of the NABH accredited Panchakarma clinics in India. Its unique hub-and-spoke operational model allows for significant cross-selling opportunities, optimizing resource utilization.

**Investor Implications:** The company is positioned favorably for sustainable growth, supported by its innovative service offerings and expanding footprint. Continued investment in operational efficiencies and enhanced service delivery could yield substantial returns for investors moving forward.